Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rivogenlecleucel
- Development stage
- Phase 3
- Lead developer
- Bellicum Pharmaceuticals
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Rivogenlecleucel, also known as BPX-501 T cells, is a donor T-cell therapy. It is being investigated for treating patients with recurrent blood cancers after stem cell transplant. The therapy involves intravenous infusion of rivogenlecleucel, with potential subsequent rimiducid infusions to manage adverse events such as acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia, or encephalopathy.
- Brand names
- Rivo-cel
- Other names
- BPX-501 T cellsBPX501 T cellsBPX 501 T cells
02
Targets
Beyond the preview
Go deeper on rivogenlecleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rivogenlecleucel.